Investors Get Second Shot at Baxter Class Action

, The Litigation Daily


Dealing a blow to defense counsel at Skadden, the court resurrected shareholder derivative claims that Baxter's board cost the company at least $550 million by failing to address chronic problems with its Colleague line of infusion pumps.

This premium content is reserved for American Lawyer subscribers.

Continue reading by getting started with a subscription.

Already a subscriber? Log in now

What's being said

Comments are not moderated. To report offensive comments, click here.

Preparing comment abuse report for Article #1202616121369

Thank you!

This article's comments will be reviewed.